Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Cytomos Limited, based in Edinburgh, United Kingdom, specializes in developing advanced technologies for cell sorting and analysis in laboratory research and clinical diagnostics. Established in 2011, the company focuses on its patented Dielectric Spectroscopy (CDS™) technology, which allows for unbiased, label-free analysis of individual cells with single-cell resolution. This technology is particularly valuable in the biopharma and cell therapy sectors, as it enables automated and quantitative assessment of samples, aiding in phenotypic drug discovery and stem cell therapy. By leveraging proprietary machine learning algorithms, Cytomos provides deep insights into bioprocesses, enhancing the efficiency of cell-based diagnostics and enabling researchers to make informed decisions regarding dosage and treatment protocols.
BioCaptiva
Seed Round in 2022
BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
ŌGI Bio is a newly formed start-up company from The University of Edinburgh with the mission to revolutionize the way that microbes are grown and managed.
Carcinotech is focused on treating cancers and is based at the Roslin Innovation Centre on the outskirts of Edinburgh.
Axol Bioscience Ltd. is a biotechnology company based in Little Chesterford, United Kingdom, specializing in human cell culture systems for medical research, disease modeling, and drug discovery. The company produces a variety of human cells, including iPSC-derived cells like cardiomyocytes and neural stem cells, as well as primary cells such as endothelial and muscle cells. Axol also offers essential media and reagents, including cell culture media and growth supplements, to support researchers in their work. Additionally, the company provides custom services such as cell and tissue sourcing, iPSC reprogramming, differentiation into various cell types, and genome editing. Axol's products and services are utilized by pharmaceutical companies and research institutions worldwide, with distribution channels spanning multiple countries. Established in 2012, Axol is located in a notable innovation hub, Chesterford Research Park, in Cambridge, UK.
Kynos Therapeutics develops KMO inhibitors across key indications in inflammation, immunity, and metabolism.
Rhizocore Technologies specializes in the production of locally-adapted mycorrhizal fungi designed to improve the success of tree planting initiatives. By developing a platform that focuses on enhancing the growth conditions for trees, the company aims to facilitate woodland regeneration and increase overall forest productivity. Its innovative approach addresses the needs of the forestry market, providing effective solutions for sustainable forestry practices.
WellFish Diagnostics is on a mission to enhance the sustainability of the aquaculture industry by increasing productivity resulting from improved fish health and welfare. The company was founded in 2021 by Brian Quinn and is headquartered in Bridge of Weir, United Kingdom. .
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.
Dyneval specializes in portable technology for cattle semen analysis, focusing on the precise measurement of semen quality. Its innovative technology assesses semen motility under quasi-in-vivo conditions, providing valuable insights into spermatozoa behavior. By utilizing dynescan data, Dyneval aids in informing breeding plans and confirming semen quality throughout the supply chain. This approach not only enhances livestock production but also contributes to improved food security and reduced methane emissions, allowing farmers to address issues related to poor conception rates effectively.
EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. Founded in 2017, the company focuses on creating microbiome-modulating drugs derived from bacterial communities in the human gastrointestinal tract. These products aim to restore health and prevent bacterial infections by addressing imbalances in gut bacteria associated with various diseases. EnteroBiotix is dedicated to developing both allogenic and autologous microbial therapeutics to meet the needs of patients with serious unmet medical conditions, thereby enabling healthcare providers to effectively prevent and treat debilitating infections and diseases.
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, that focuses on developing innovative immunotherapies aimed at modulating macrophages to enhance the body's immune response against tumors. Established in 2018, the company is dedicated to creating first-in-class treatments that target the immunosuppressive tumor microenvironment. By leveraging disease-specific macrophage biology, Macomics aims to harness the immune system's potential, providing clinical benefits to a broader range of cancer patients.
ENOUGH, formerly known as 3fbio Ltd., is a technology spin-out from the University of Strathclyde, established to develop and commercialize innovative patented technology for the production of mycoprotein, a meat-free food product. The company employs integrated fermentation processes that combine the production of mycoprotein with existing bio-refinery operations, which also generate bioethanol and animal feed as co-products. By utilizing glucose syrup as feedstock for mycoprotein and carbohydrate feedstock for bioethanol, ENOUGH aims to enhance production economics while promoting sustainable food solutions. Incorporated in 2015 and based in Glasgow, United Kingdom, the company focuses on transforming the food, fuel, and feed sectors through its advanced production methods.
BioCaptiva
Seed Round in 2021
BioCaptiva develops liquid biopsy technology devices to diagnose and monitoring to detect cancers.
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
RAB Microfluidics specializes in developing innovative lab-on-a-chip technology aimed at transforming oil analysis processes. By utilizing patented microfluidic technology, the company offers real-time diagnostics for lubricated machinery, enabling early detection of potential failures and preventing costly equipment breakdowns. This dynamic approach provides clients with laboratory-quality data and actionable insights for effective asset condition management, significantly reducing costs compared to traditional methods. Founded on a decade of research from the University of Aberdeen, RAB Microfluidics is recognized as a pioneer in microfluidic technology for oil applications in Europe. With a dedicated advisory team boasting over 60 years of expertise, the company is committed to addressing the needs of diverse industries, including oil and gas, aerospace, and power generation, by making oil testing mobile, rapid, and routine.
Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Bio-Images Drug Delivery Ltd, located in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers comprehensive services that include troubleshooting, formulation development, and both in vitro and in vivo testing. A key feature of their offerings is the patented OralogiK technology, which allows for precise control of drug release. This technology has been validated in clinical studies and enables the oral administration of single, multi-dose, or combination drugs at specific intervals ranging from one to twelve hours after ingestion. The benefits of this system include targeted night-time dosing, multi-phased drug delivery, and the ability to direct drugs to specific areas within the digestive system. Additionally, Bio-Images Drug Delivery employs gamma scintigraphy to assess the in vivo behavior of formulations, providing crucial data on disintegration times, gastric emptying, and gastrointestinal transit. The company's clinical division supports the entire clinical trial process, from protocol development to regulatory submissions and the production of compliant study reports.
Aurum Biosciences Ltd develops pharmaceuticals. The company’s products and technology include Perfluorocarbon which carry oxygen to organs and tissues; Magnetic Resonance Imaging which is a medical imaging technique that does not use ionising radiation and Proprietary image analysis software which provides accurate analyses of images of the stroke patient’s brain. Aurum Biosciences Ltd was founded in 2010 and is headquartered in Glasgow, United Kingdom.
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders and other rare diseases. It offers proprietary AAV technology, manufacturing capabilities, and a robust pipeline of in-house clinical programs for clients in the medical biopharmaceutical industry. Its pipeline includes clinical-stage programs in Pompe disease and congestive heart failure and a diverse preclinical portfolio of therapeutics targeting neuromuscular, CNS, and other diseases, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid, and promoter library. Asklepios BioPharmaceutical was founded in 2001 and is headquartered in Research Triangle Park, North Carolina.
Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, that focuses on developing innovative immunotherapies aimed at modulating macrophages to enhance the body's immune response against tumors. Established in 2018, the company is dedicated to creating first-in-class treatments that target the immunosuppressive tumor microenvironment. By leveraging disease-specific macrophage biology, Macomics aims to harness the immune system's potential, providing clinical benefits to a broader range of cancer patients.
New Wave Foods, Inc. specializes in producing and selling plant-based seafood products, focusing primarily on sustainable shrimp alternatives. Founded in 2015 and headquartered in San Francisco, California, the company offers a variety of items, including sautéed, grilled, breaded, and fried shrimp, as well as shrimp tacos and salads. Its products are made from sustainably sourced seaweed and soy protein, enriched with natural flavors and essential amino acids, providing a healthy, low-calorie, and zero-cholesterol option for consumers. Targeting the culinary market in the United States, New Wave Foods aims to preserve and enrich seafood traditions through its innovative plant-based offerings.
Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology.
Censo Biotechnologies Ltd engages in the development of stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. Its induced pluripotent stem cells (iPSCs) technology enables creation of stem cells in the laboratory from any person who donates a skin or blood sample. The company provides services, such as human tissue sample procurement, iPSC generation, iPSC genome editing, differentiated cell protocol development and industrialization, production of differentiated cells of specific lineages, cell based assay development, and compound screening. Censo Biotechnologies Ltd was formerly known as Roslin Cellab Limited and changed its name to Censo Biotechnologies Ltd in May 2016. The company was founded in 2008 and is based in Edinburgh, United Kingdom with an additional office in Cambridge, United Kingdom.
Amphista Therapeutics Limited is a biopharmaceutical company based in Motherwell, United Kingdom, founded in 2017. The company specializes in targeted protein degradation technology, which is aimed at developing innovative cancer therapeutics. Amphista's approach leverages the body's natural processes to selectively degrade and eliminate proteins that contribute to disease progression. By advancing next-generation therapeutics, the company seeks to improve treatment efficacy and enhance patient outcomes across a range of diseases. Amphista's research focuses on identifying novel methods to modulate the cell's degradation machinery, thereby addressing the underlying mechanisms of various conditions.
Censo Biotechnologies Ltd engages in the development of stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. Its induced pluripotent stem cells (iPSCs) technology enables creation of stem cells in the laboratory from any person who donates a skin or blood sample. The company provides services, such as human tissue sample procurement, iPSC generation, iPSC genome editing, differentiated cell protocol development and industrialization, production of differentiated cells of specific lineages, cell based assay development, and compound screening. Censo Biotechnologies Ltd was formerly known as Roslin Cellab Limited and changed its name to Censo Biotechnologies Ltd in May 2016. The company was founded in 2008 and is based in Edinburgh, United Kingdom with an additional office in Cambridge, United Kingdom.
MiAlgae Ltd, founded in 2016 and based in Edinburgh, United Kingdom, specializes in the production of microalgal products designed to replace fishmeal in livestock feeds. The company focuses on creating nutrient-rich supplements high in Omega-3 fatty acids and proteins, essential for aquaculture and other livestock. By utilizing wastewater remediation in its production process, MiAlgae operates within a circular economy framework, which helps lower production costs and enhances competitiveness in the £340 billion global livestock feed industry. This innovative approach not only contributes to sustainable livestock production but also addresses the growing demand for alternative protein sources in animal nutrition.
Wobble Genomics is a biotechnology firm focused on enhancing the efficiency of RNA and DNA sequencing to facilitate the discovery and detection of nucleic acid biomarkers. The company employs a blend of biochemistry and bioinformatics to achieve unprecedented sensitivity and accuracy in identifying novel biomarkers. By optimizing sampling efficiency during sequencing, Wobble Genomics aims to reduce costs for medical researchers, thereby advancing the field of genomic analysis and improving diagnostic capabilities.
ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, specializing in the development and supply of recombinant blood factors for the treatment of hemophilia, a genetic disorder that impairs the body's ability to clot blood. Founded in 2009, the company focuses on creating Factor VIII, a complex protein critical for coagulation, and is also engaged in developing commercially viable and Good Manufacturing Practice (GMP) compatible cell lines for producing recombinant Factor VIII. By utilizing proprietary high-expressing cell lines alongside single-use disposable manufacturing technology, ProFactor Pharma aims to provide healthcare institutions with more accessible and cost-effective treatment options for patients suffering from hemophilia, who face serious health risks due to their condition.
MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients with autoimmune diseases and cancers. Established in 2009, the company is known for its lead product, annexuzlimab, a monoclonal antibody designed to address various autoimmune conditions. MedAnnex aims to create first-in-class antibody therapies that significantly enhance the quality of life for individuals affected by these serious health issues. Through its research and development efforts, the company is committed to advancing therapeutic options in the biotechnology sector.
CuanTec Ltd is a Scottish biotechnology company based in Motherwell, specializing in the production of biodegradable plastic films for the food industry. Founded in 2016, CuanTec utilizes a sustainable approach by extracting chitin from waste generated by the fisheries sector, particularly from langoustines sourced from the pollution-free waters of the North Atlantic. This extraction is achieved through a low-energy fermentation process that employs harmless bacteria, resulting in a high-quality product with minimal waste. The company’s compostable and antimicrobial bioplastics serve as an environmentally friendly alternative to conventional packaging, aiming to reduce plastic pollution and food waste while extending the shelf life of fresh food. By employing a circular economy model, CuanTec effectively transforms marine waste into valuable packaging solutions.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
Censo Biotechnologies Ltd engages in the development of stem cell technology company providing human cells and contract research services for drug discovery, toxicity testing and cell banking. Its induced pluripotent stem cells (iPSCs) technology enables creation of stem cells in the laboratory from any person who donates a skin or blood sample. The company provides services, such as human tissue sample procurement, iPSC generation, iPSC genome editing, differentiated cell protocol development and industrialization, production of differentiated cells of specific lineages, cell based assay development, and compound screening. Censo Biotechnologies Ltd was formerly known as Roslin Cellab Limited and changed its name to Censo Biotechnologies Ltd in May 2016. The company was founded in 2008 and is based in Edinburgh, United Kingdom with an additional office in Cambridge, United Kingdom.
EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. Founded in 2017, the company focuses on creating microbiome-modulating drugs derived from bacterial communities in the human gastrointestinal tract. These products aim to restore health and prevent bacterial infections by addressing imbalances in gut bacteria associated with various diseases. EnteroBiotix is dedicated to developing both allogenic and autologous microbial therapeutics to meet the needs of patients with serious unmet medical conditions, thereby enabling healthcare providers to effectively prevent and treat debilitating infections and diseases.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
Greengage Agritech, founded in 2008 and located at the Roslin Institute of Edinburgh University, focuses on enhancing the agricultural sector through innovative technologies. The company develops systems aimed at improving productivity and reducing operational costs for farmers, particularly in the realm of livestock management. Their product offerings include induction-powered LED lighting, advanced sensors, web applications, and data analytics tools. These technologies enable remote monitoring of environmental conditions and animal behavior, helping farming businesses optimize operations, increase production efficiency, and promote sustainable agricultural practices. By integrating these solutions, Greengage Agritech supports farmers in achieving better overall well-being for their livestock while ensuring profitable development.
Greengage Agritech, founded in 2008 and located at the Roslin Institute of Edinburgh University, focuses on enhancing the agricultural sector through innovative technologies. The company develops systems aimed at improving productivity and reducing operational costs for farmers, particularly in the realm of livestock management. Their product offerings include induction-powered LED lighting, advanced sensors, web applications, and data analytics tools. These technologies enable remote monitoring of environmental conditions and animal behavior, helping farming businesses optimize operations, increase production efficiency, and promote sustainable agricultural practices. By integrating these solutions, Greengage Agritech supports farmers in achieving better overall well-being for their livestock while ensuring profitable development.
Synpromics Ltd. specializes in the development and commercialization of synthetic promoters that regulate gene expression. Founded in 2010 and located in Edinburgh, United Kingdom, the company focuses on enhancing the safety and efficacy of cell and gene therapies through its proprietary genomics and bioinformatics technologies. By utilizing a comprehensive bioinformatics database, Synpromics enables the design and selection of product-specific promoters, which supports biological researchers and developers in creating innovative solutions in the fields of AgBio and bioprocessing. As of 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.
ENOUGH, formerly known as 3fbio Ltd., is a technology spin-out from the University of Strathclyde, established to develop and commercialize innovative patented technology for the production of mycoprotein, a meat-free food product. The company employs integrated fermentation processes that combine the production of mycoprotein with existing bio-refinery operations, which also generate bioethanol and animal feed as co-products. By utilizing glucose syrup as feedstock for mycoprotein and carbohydrate feedstock for bioethanol, ENOUGH aims to enhance production economics while promoting sustainable food solutions. Incorporated in 2015 and based in Glasgow, United Kingdom, the company focuses on transforming the food, fuel, and feed sectors through its advanced production methods.
Biotangents Ltd., founded in 2015 and based in Glasgow, United Kingdom, specializes in designing and building biological pathways for the production of valuable natural materials. The company utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from various DNA components. Among its innovations is the development of terpenoid biosynthesis strains and the Short Sequence Randomisation technology for DNA randomisation. Biotangents has also conceptualized Moduleic Sensing, a modular cell-free nucleic acid detection technology, which led to the creation of a diagnostic test for identifying infectious diseases in livestock. This veterinary diagnostic device employs isothermal amplification technology, enabling precise detection without significant technical demands and allowing for quick adaptation to new targets. The solutions provided by Biotangents aim to mitigate the impact of infectious diseases in livestock, thereby enhancing the efficiency of animal protein production.
Bio-Images Drug Delivery Ltd, located in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers comprehensive services that include troubleshooting, formulation development, and both in vitro and in vivo testing. A key feature of their offerings is the patented OralogiK technology, which allows for precise control of drug release. This technology has been validated in clinical studies and enables the oral administration of single, multi-dose, or combination drugs at specific intervals ranging from one to twelve hours after ingestion. The benefits of this system include targeted night-time dosing, multi-phased drug delivery, and the ability to direct drugs to specific areas within the digestive system. Additionally, Bio-Images Drug Delivery employs gamma scintigraphy to assess the in vivo behavior of formulations, providing crucial data on disintegration times, gastric emptying, and gastrointestinal transit. The company's clinical division supports the entire clinical trial process, from protocol development to regulatory submissions and the production of compliant study reports.
TC BioPharm’s mission is to develop and commercialise innovative cell-based products to treat disease, improving patient health and Quality of Life.
TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell®, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.
Causeway Therapeutics Ltd is a biopharmaceutical company based in Glasgow, United Kingdom, that specializes in developing microRNA products aimed at treating tendon injuries and disorders in both humans and horses. Founded in 2015 as a spin-out from the University of Glasgow, the company has leveraged academic research to create innovative therapies in the orthobiologic space. Its primary products include EquiMiR, designed to treat equine tendinopathy by mimicking natural microRNA with enhanced pharmacological properties, and TenoMiR, which restores critical microRNA levels to improve tendon health and strength. The company's focus on microRNA therapy is supported by a solid foundation of intellectual property and scientific evidence demonstrating its efficacy in addressing tendinopathies.
ENOUGH, formerly known as 3fbio Ltd., is a technology spin-out from the University of Strathclyde, established to develop and commercialize innovative patented technology for the production of mycoprotein, a meat-free food product. The company employs integrated fermentation processes that combine the production of mycoprotein with existing bio-refinery operations, which also generate bioethanol and animal feed as co-products. By utilizing glucose syrup as feedstock for mycoprotein and carbohydrate feedstock for bioethanol, ENOUGH aims to enhance production economics while promoting sustainable food solutions. Incorporated in 2015 and based in Glasgow, United Kingdom, the company focuses on transforming the food, fuel, and feed sectors through its advanced production methods.
Greengage Agritech, founded in 2008 and located at the Roslin Institute of Edinburgh University, focuses on enhancing the agricultural sector through innovative technologies. The company develops systems aimed at improving productivity and reducing operational costs for farmers, particularly in the realm of livestock management. Their product offerings include induction-powered LED lighting, advanced sensors, web applications, and data analytics tools. These technologies enable remote monitoring of environmental conditions and animal behavior, helping farming businesses optimize operations, increase production efficiency, and promote sustainable agricultural practices. By integrating these solutions, Greengage Agritech supports farmers in achieving better overall well-being for their livestock while ensuring profitable development.
Ryboquin™ uses its expertise to turn under-developed intellectual property ideas into viable commercial realities. Founded in Scotland, Ryboquin Ltd is a privately held, virtual pharmaceutical company focused on commercialising patented technologies in the area of human cancer medicine.
Founded in Scotland, Ryboquin is a privately held, virtual pharmaceutical company focused on commercializing patented technologies in the area of human cancer medicine.
EnteroBiotix Limited is a biotechnology company based in Edinburgh, United Kingdom, that specializes in the research, development, and commercialization of orally available products for fecal microbiota transplantation. Founded in 2017, the company focuses on creating microbiome-modulating drugs derived from bacterial communities in the human gastrointestinal tract. These products aim to restore health and prevent bacterial infections by addressing imbalances in gut bacteria associated with various diseases. EnteroBiotix is dedicated to developing both allogenic and autologous microbial therapeutics to meet the needs of patients with serious unmet medical conditions, thereby enabling healthcare providers to effectively prevent and treat debilitating infections and diseases.
Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.
Synpromics Ltd. specializes in the development and commercialization of synthetic promoters that regulate gene expression. Founded in 2010 and located in Edinburgh, United Kingdom, the company focuses on enhancing the safety and efficacy of cell and gene therapies through its proprietary genomics and bioinformatics technologies. By utilizing a comprehensive bioinformatics database, Synpromics enables the design and selection of product-specific promoters, which supports biological researchers and developers in creating innovative solutions in the fields of AgBio and bioprocessing. As of 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
TC BioPharm’s mission is to develop and commercialise innovative cell-based products to treat disease, improving patient health and Quality of Life.
TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell®, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.
Greengage Agritech, founded in 2008 and located at the Roslin Institute of Edinburgh University, focuses on enhancing the agricultural sector through innovative technologies. The company develops systems aimed at improving productivity and reducing operational costs for farmers, particularly in the realm of livestock management. Their product offerings include induction-powered LED lighting, advanced sensors, web applications, and data analytics tools. These technologies enable remote monitoring of environmental conditions and animal behavior, helping farming businesses optimize operations, increase production efficiency, and promote sustainable agricultural practices. By integrating these solutions, Greengage Agritech supports farmers in achieving better overall well-being for their livestock while ensuring profitable development.
Alfacyte Ltd. develops an immunoregulatory formulation for the oral treatment of food allergies based on the immunological activities of two candidate cytokines, with adjuvant-like activities. Its immunoregulatory combination therapy is used for the oral treatment of peanut allergy.
MOFgen Ltd is an award winning VC-backed SME spin-out from the University of St Andrews and is the first company to commercialise MOFs for medical and therapeutic applications. The company’s patented technology was pioneered in the laboratories of world renowned porous material scientist Prof Russell Morris FRS within the School of Chemistry at St Andrews. With roots in the leading research group of its field, MOFgen is exploiting its strong IP and knowhow assets in the areas of MOF design, application, manufacturing and formulation to deliver cutting edge solutions to healthcare challenges. Through an ethos of innovation and collaboration, MOFgen works closely with its partners, to develop bespoke solutions to prevent healthcare associated infections, avoid bacterial resistance, heal chronic wounds and address arterial access.
CuanTec Ltd is a Scottish biotechnology company based in Motherwell, specializing in the production of biodegradable plastic films for the food industry. Founded in 2016, CuanTec utilizes a sustainable approach by extracting chitin from waste generated by the fisheries sector, particularly from langoustines sourced from the pollution-free waters of the North Atlantic. This extraction is achieved through a low-energy fermentation process that employs harmless bacteria, resulting in a high-quality product with minimal waste. The company’s compostable and antimicrobial bioplastics serve as an environmentally friendly alternative to conventional packaging, aiming to reduce plastic pollution and food waste while extending the shelf life of fresh food. By employing a circular economy model, CuanTec effectively transforms marine waste into valuable packaging solutions.
Greengage Agritech, founded in 2008 and located at the Roslin Institute of Edinburgh University, focuses on enhancing the agricultural sector through innovative technologies. The company develops systems aimed at improving productivity and reducing operational costs for farmers, particularly in the realm of livestock management. Their product offerings include induction-powered LED lighting, advanced sensors, web applications, and data analytics tools. These technologies enable remote monitoring of environmental conditions and animal behavior, helping farming businesses optimize operations, increase production efficiency, and promote sustainable agricultural practices. By integrating these solutions, Greengage Agritech supports farmers in achieving better overall well-being for their livestock while ensuring profitable development.
Greengage Agritech, founded in 2008 and located at the Roslin Institute of Edinburgh University, focuses on enhancing the agricultural sector through innovative technologies. The company develops systems aimed at improving productivity and reducing operational costs for farmers, particularly in the realm of livestock management. Their product offerings include induction-powered LED lighting, advanced sensors, web applications, and data analytics tools. These technologies enable remote monitoring of environmental conditions and animal behavior, helping farming businesses optimize operations, increase production efficiency, and promote sustainable agricultural practices. By integrating these solutions, Greengage Agritech supports farmers in achieving better overall well-being for their livestock while ensuring profitable development.
Aurum Biosciences Ltd develops pharmaceuticals. The company’s products and technology include Perfluorocarbon which carry oxygen to organs and tissues; Magnetic Resonance Imaging which is a medical imaging technique that does not use ionising radiation and Proprietary image analysis software which provides accurate analyses of images of the stroke patient’s brain. Aurum Biosciences Ltd was founded in 2010 and is headquartered in Glasgow, United Kingdom.
Caldan Therapeutics Ltd is a biotechnology company that originated as a spinout from the University of Glasgow and the University of Southern Denmark. The company focuses on the development of novel therapeutics that target free fatty acid receptors, which play a significant role in the pathophysiology of metabolic diseases, particularly Type 2 Diabetes (T2D). Through a collaboration between Professor Graeme Milligan and Professor Trond Ulven, Caldan Therapeutics aims to address various aspects of T2D, including insulin secretion, insulin sensitivity, and islet cell protection. In addition to T2D, there is potential for the company's therapeutics to be applied in treating other conditions such as non-alcoholic steatohepatitis and inflammatory diseases.
Taragenyx Ltd. is an orthopedic biotechnology company based in Glasgow, United Kingdom, focused on developing innovative self-healing implant technologies aimed at enhancing the body's natural repair processes. Established in 2010 and formerly known as RRG Coatings Ltd., the company specializes in a range of applications, including spine, trauma, and extremities, as well as biologics. Taragenyx's product line features therapeutic implants, surface-active coatings, and skeletal implants designed to address surgical complications associated with infection, pain, and thrombosis. By integrating active pharmaceuticals and biologics into the implant coatings, Taragenyx aims to facilitate accelerated bone growth, promote faster healing, and minimize the risk of postoperative complications.
Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, specializing in the design and supply of tuneable peptide hydrogels for various applications in cell culture research. Established in 2012, the company focuses on providing hydrogels that closely mimic the chemical and physical properties of natural tissues, enabling researchers to grow, proliferate, and manipulate cells within realistic 3D environments. Their products are utilized in fundamental cell research, toxicology and drug development, as well as cancer cell research, and aim to replace animal testing methods. Biogelx's patented hydrogel systems are marketed globally, offering academic institutions, medical researchers, and pharmaceutical companies a competitive alternative to existing 3D cell culture solutions. Additionally, these hydrogels hold potential for future applications in cell therapy and regenerative medicine.
Clyde Biosciences Ltd. specializes in developmental drug testing solutions, focusing on cardiac cell analysis to provide insights into drug mechanisms and toxicity. The company has developed cellOPTIQ, an optical action potential assay that helps clients assess the cardiotoxicity risk of new and existing drugs by evaluating their effects on human cells. Additionally, Clyde Biosciences offers XTENDSR, which allows for direct measurements of drug-induced changes in cardiac sarcoplasmic reticulum function. By delivering human-relevant cardiomyocyte functional data, the company aids pharmaceutical and biotechnology firms in mitigating risks during drug development. Founded in 2012 and based in Glasgow, United Kingdom, Clyde Biosciences serves clients both domestically and internationally.
ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, specializing in the development and supply of recombinant blood factors for the treatment of hemophilia, a genetic disorder that impairs the body's ability to clot blood. Founded in 2009, the company focuses on creating Factor VIII, a complex protein critical for coagulation, and is also engaged in developing commercially viable and Good Manufacturing Practice (GMP) compatible cell lines for producing recombinant Factor VIII. By utilizing proprietary high-expressing cell lines alongside single-use disposable manufacturing technology, ProFactor Pharma aims to provide healthcare institutions with more accessible and cost-effective treatment options for patients suffering from hemophilia, who face serious health risks due to their condition.
Relitect Limited engages in developing a technology for the detection of binding events, which can be used for the analysis of proteins, small molecules, and nucleic acids for clinical diagnostics and life sciences industries. The company was incorporated in 2014 and is based in Motherwell, United Kingdom.
DestiNA Genomics Ltd. is a molecular diagnostic company based in Edinburgh, United Kingdom, specializing in the detection of nucleic acids and single nucleotide polymorphisms (SNPs). Founded in 2010 as a spin-out from the University of Edinburgh, the company has developed a unique, chemical-based system that is distinct from traditional enzymatic methods. DestiNA offers a range of reagents and probes for the detection of nucleic acids and mutations, as well as assay sets for drug profiling and development. Its technology is particularly effective for direct detection of micro-RNAs and is being integrated into various detection platforms, including colorimetric, fluorescent, and electrochemical systems. DestiNA Genomics has also established a subsidiary in Spain, DestiNA Genomica SL, to exploit its technologies in collaboration with local partners. The Spanish subsidiary has received funding from the Technological Fund of Invest in Spain to support its research and development initiatives.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, specializing in the development and supply of recombinant blood factors for the treatment of hemophilia, a genetic disorder that impairs the body's ability to clot blood. Founded in 2009, the company focuses on creating Factor VIII, a complex protein critical for coagulation, and is also engaged in developing commercially viable and Good Manufacturing Practice (GMP) compatible cell lines for producing recombinant Factor VIII. By utilizing proprietary high-expressing cell lines alongside single-use disposable manufacturing technology, ProFactor Pharma aims to provide healthcare institutions with more accessible and cost-effective treatment options for patients suffering from hemophilia, who face serious health risks due to their condition.
Synpromics Ltd. specializes in the development and commercialization of synthetic promoters that regulate gene expression. Founded in 2010 and located in Edinburgh, United Kingdom, the company focuses on enhancing the safety and efficacy of cell and gene therapies through its proprietary genomics and bioinformatics technologies. By utilizing a comprehensive bioinformatics database, Synpromics enables the design and selection of product-specific promoters, which supports biological researchers and developers in creating innovative solutions in the fields of AgBio and bioprocessing. As of 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.
Edinburgh Molecular Imaging Limited is a biotechnology company based in Edinburgh, United Kingdom, founded in 2014. The company specializes in optical molecular imaging technology that facilitates image-guided therapy for the detection, diagnosis, and monitoring of diseases. It focuses on the discovery and development of small molecules and peptides that can be conjugated with fluorescent dyes, allowing for real-time disease detection during interventional procedures, such as surgery. Edinburgh Molecular Imaging has raised over £15 million in non-dilutive funding from organizations like the Wellcome Trust, EPSRC, and MRC to advance its innovative SMART Agents, which enhance molecular imaging capabilities. The team behind the company comprises experienced scientists and clinicians with extensive expertise in medicinal chemistry, biochemistry, cell biology, and clinical development, positioning the company to contribute significantly to the field of medical imaging.
Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, specializing in the development and supply of high-quality reagents, kits, and drug discovery services. Founded in 2009, Ubiquigent focuses on protein degradation, particularly through the innovation of deubiquitylase (DUB) enzyme inhibitors. The company caters to the life science research community by providing drug discovery assay development and compound profiling services, targeting the ubiquitin and ubiquitin-like signaling systems. Ubiquigent collaborates with academic researchers and pharmaceutical scientists to advance drug discovery related to DUB modulators, which hold promise for addressing significant therapeutic needs. Additionally, the company is building a strong intellectual property portfolio that includes inhibitors and compounds aimed at enhancing drug development initiatives.
ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, specializing in the development and supply of recombinant blood factors for the treatment of hemophilia, a genetic disorder that impairs the body's ability to clot blood. Founded in 2009, the company focuses on creating Factor VIII, a complex protein critical for coagulation, and is also engaged in developing commercially viable and Good Manufacturing Practice (GMP) compatible cell lines for producing recombinant Factor VIII. By utilizing proprietary high-expressing cell lines alongside single-use disposable manufacturing technology, ProFactor Pharma aims to provide healthcare institutions with more accessible and cost-effective treatment options for patients suffering from hemophilia, who face serious health risks due to their condition.
Fixed Phage was founded with the aim of developing new products for various industries from our platform technology. Each of our core technologies is comprehensively described and protected by our IP portfolio. We work at our custom designed laboratory and support infrastructure facilities located at the prestigious West of Scotland Science Park. Our in-house abilities include all work required to identify, manufacture and work with bacteriophage. Fixed Phage continually invests in innovation and our team presents at conferences and exhibitions around the world. To learn about whether we will be presenting near you, please follow us on social media.
Taragenyx Ltd. is an orthopedic biotechnology company based in Glasgow, United Kingdom, focused on developing innovative self-healing implant technologies aimed at enhancing the body's natural repair processes. Established in 2010 and formerly known as RRG Coatings Ltd., the company specializes in a range of applications, including spine, trauma, and extremities, as well as biologics. Taragenyx's product line features therapeutic implants, surface-active coatings, and skeletal implants designed to address surgical complications associated with infection, pain, and thrombosis. By integrating active pharmaceuticals and biologics into the implant coatings, Taragenyx aims to facilitate accelerated bone growth, promote faster healing, and minimize the risk of postoperative complications.
Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, focused on developing and commercializing medical devices and pharmaceuticals that utilize mimetics of extra-alveolar lamellar bodies. Established in 2006 and renamed in 2007, the company has harnessed the therapeutic potential of its proprietary product, Lamellasomes, a synthetic substance designed to mimic the actions of natural lamellar bodies. These products aim to treat various conditions, including respiratory diseases such as cystic fibrosis, as well as complications from radiotherapy-induced xerostomia and dry eye disease. Lamellar Biomedical is dedicated to advancing innovative therapies to address significant medical needs.
Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, specializing in the design and supply of tuneable peptide hydrogels for various applications in cell culture research. Established in 2012, the company focuses on providing hydrogels that closely mimic the chemical and physical properties of natural tissues, enabling researchers to grow, proliferate, and manipulate cells within realistic 3D environments. Their products are utilized in fundamental cell research, toxicology and drug development, as well as cancer cell research, and aim to replace animal testing methods. Biogelx's patented hydrogel systems are marketed globally, offering academic institutions, medical researchers, and pharmaceutical companies a competitive alternative to existing 3D cell culture solutions. Additionally, these hydrogels hold potential for future applications in cell therapy and regenerative medicine.
Touch Bionics Limited, located in Livingston, Scotland, specializes in the development and marketing of advanced upper-limb prosthetics aimed at patients with upper-limb deficiencies. The company's notable products include the i-LIMB Hand, a multi-articulating bionic hand designed to assist amputees, and self-contained powered Prosthetic Digits, which offer functionality for individuals with partial hand loss. Additionally, Touch Bionics provides ProDigits, a solution for patients missing fingers. Their offerings extend to highly realistic passive functional prostheses, which are designed to closely resemble the natural appearance of the wearer. Touch Bionics distributes its innovative products across various regions, including the United States, Europe, Asia, and parts of South America and Africa. Established in 2003, the company was previously known as Touch EMAS Limited and rebranded in 2005. As of 2016, Touch Bionics operates as a subsidiary of Ossur Hf.
TPP is a UK-based preclinical-stage drug development company focused on nervous system disorders, immunology, and oncology. They in-license and develop intellectual properties obtained from research institutions, and the resultant products are either distributed via spin-outs or through licensing to the biotech/pharmaceutical sector.
MGB Biopharma Limited is a biopharmaceutical company based in Bellshill, United Kingdom, focused on developing a novel class of anti-infective medicines derived from DNA Minor Groove Binders (MGB). Established in 2009, the company is dedicated to creating small molecule antibacterial agents effective against both multi-resistant and susceptible Gram-positive pathogens. One of its key products, MGB-BP-3, is being developed in an oral formulation for the treatment of Clostridium difficile associated disease. By targeting bacteria through a unique mode of action, MGB Biopharma aims to address the challenge of antibiotic resistance, offering healthcare providers more effective treatment options for bacterial infections. The experienced team at MGB Biopharma leverages expertise from the pharmaceutical and biotechnology sectors to drive its innovative research and development efforts.
Lab901
Venture Round in 2009
Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.
Big DNA Ltd was set up in 2007 by Dr John March, as a spin out company from the Moredun Research Institute at Edinburgh University, to further develop and commercialise new vaccination technologies. Based at Roslin BioCentre, the company currently employs 7 people.
Lab901
Venture Round in 2008
Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.
CXR Biosciences is advancing and commercializing innovative approaches to transform the drug development and chemical safety assessment process. As well as introducing new technology platforms to the marketplace, CXR also helps customers to take their candidate compounds through development efficiently, or to resolve problems that have been encountered, through the provision of customized solutions. The company has business relationships with over sixty customers and collaborators, including pharmaceutical companies, chemical companies, biotechnology companies, leading universities and research institutions.
Big DNA Ltd was set up in 2007 by Dr John March, as a spin out company from the Moredun Research Institute at Edinburgh University, to further develop and commercialise new vaccination technologies. Based at Roslin BioCentre, the company currently employs 7 people.
Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.
DC Biosciences Ltd specializes in providing proteomics services and molecular biology solutions to pharmaceutical and biotech companies, facilitating the development of drugs. The company offers a comprehensive technology portfolio, focusing on quantitative proteomics to support preclinical activities in drug discovery. Its services include biomarker discovery and validation, as well as drug re-profiling and repositioning. Key products offered by DC Biosciences include stable isotope labeling with amino acids in cell culture (SILAC) reagents, such as SILAC cell culture media and dialysed sera for SILAC applications, along with click chemistry reagents. Established in 2006 and originally known as Dundee Cell Products Ltd, the company rebranded to DC Biosciences Ltd in 2016 and is headquartered in Dundee, United Kingdom.
Nandi Proteins Limited is a technology-driven company based in Edinburgh, United Kingdom, focused on enhancing the functional properties of proteins in food manufacturing and nutrition. Established in 2000 and spun out of Heriot Watt University in 2001, the company specializes in patented processes that improve common proteins such as whey, egg, and soy. Nandi Proteins aims to be a leader in denatured protein technology, facilitating growth through direct trading of value-added proteins and strategic licensing agreements with industry partners. Its innovative approach employs a combination of heat, time, and temperature control to modify proteins, enabling food and beverage manufacturers to achieve desirable characteristics and health benefits while efficiently extracting valuable components like enzymes.
Aquapharm is an innovative drug discovery company focussed on developing new products founded on the chemical diversity of marine micro-organisms. Their core focus is the development of novel pharmaceutical compounds leading to the development of novel antibiotics, targeting both Gram negative and Gram positive infections. In addition, Aquapharm's development pipeline is also fed by an active discovery portfolio of anti-oxidants, anti-inflammatories and novel biocatalysts.
Lab901
Venture Round in 2005
Lab901 Limited engages in the development and production of automated gel electrophories in the United Kingdom. It offers ScreenTape P200 variant, which allows scientists in expressing and purifying recombinant proteins and monoclonal antibodies to carry out SDS-PAGE and analysis; ScreenTape R6K that is developed for reproducible RNA characterisation and quality control; and ScreenTape D800, which separates DNA fragments.
NiTech Solutions Ltd. is a company based in Edinburgh, United Kingdom, specializing in the design and provision of continuous oscillatory baffled reactors and tubular reactors for various applications, including crystallization, biodiesel production, hydrogenation, polymerization, and pharmaceutical active pharmaceutical ingredients. Founded in 2003, NiTech focuses on enhancing process efficiency in the chemical, pharmaceutical, biotechnology, waste management, and food and drinks sectors. The company's innovative baffled reactor technology facilitates the mixing of liquid-liquid, liquid-solid, and gas-liquid-solid processes, enabling clients to transition from batch to continuous processes. This shift not only enhances operational efficiency but also reduces costs, energy consumption, and waste generation while improving product quality. NiTech's team comprises experts in process design, chemistry, and chemical engineering, ensuring the successful implementation of advanced and effective solutions for its clients.